Compare DAO & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | ALVO |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | China | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2019 | N/A |
| Metric | DAO | ALVO |
|---|---|---|
| Price | $11.28 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 53.6K | ★ 366.2K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.24 | $13.28 |
| Revenue Next Year | $14.60 | $18.63 |
| P/E Ratio | $72.35 | ★ $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.00 | $3.03 |
| 52 Week High | $12.96 | $11.85 |
| Indicator | DAO | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 65.73 | 44.62 |
| Support Level | $8.56 | $3.03 |
| Resistance Level | $11.37 | $3.93 |
| Average True Range (ATR) | 0.63 | 0.17 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 95.50 | 27.08 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.